Villemure Elisia, Volgraf Matthew, Jiang Yu, Wu Guosheng, Ly Cuong Q, Yuen Po-Wai, Lu Aijun, Luo Xifeng, Liu Mingcui, Zhang Shun, Lupardus Patrick J, Wallweber Heidi J A, Liederer Bianca M, Deshmukh Gauri, Plise Emile, Tay Suzanne, Wang Tzu-Ming, Hanson Jesse E, Hackos David H, Scearce-Levie Kimberly, Schwarz Jacob B, Sellers Benjamin D
Department of Discovery Chemistry, Department of Neurosciences, Department of Biochemical and Cellular Pharmacology, Department of Drug Metabolism and Pharmacokinetics, and Department of Structural Biology, Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States.
Pharmaron-Beijing Co. Ltd. , 6 Taihe Road, BDA, Beijing 100176, PR China.
ACS Med Chem Lett. 2016 Oct 31;8(1):84-89. doi: 10.1021/acsmedchemlett.6b00388. eCollection 2017 Jan 12.
The -methyl-d-aspartate receptor (NMDAR) is an ionotropic glutamate receptor, gated by the endogenous coagonists glutamate and glycine, permeable to Ca and Na. NMDAR dysfunction is associated with numerous neurological and psychiatric disorders, including schizophrenia, depression, and Alzheimer's disease. Recently, we have disclosed GNE-0723 (), a GluN2A subunit-selective and brain-penetrant positive allosteric modulator (PAM) of NMDARs. This work highlights the discovery of a related pyridopyrimidinone core with distinct structure-activity relationships, despite the structural similarity to GNE-0723. GNE-5729 (), a pyridopyrimidinone-based NMDAR PAM, was identified with both an improved pharmacokinetic profile and increased selectivity against AMPARs. We also include X-ray structure analysis and modeling to propose hypotheses for the activity and selectivity differences.
N-甲基-D-天冬氨酸受体(NMDAR)是一种离子型谷氨酸受体,由内源性协同激动剂谷氨酸和甘氨酸门控,对钙离子和钠离子具有通透性。NMDAR功能障碍与多种神经和精神疾病有关,包括精神分裂症、抑郁症和阿尔茨海默病。最近,我们发现了GNE-0723(),一种NMDAR的GluN2A亚基选择性且具有脑渗透性的正变构调节剂(PAM)。这项工作突出了一种具有独特构效关系的相关吡啶并嘧啶酮核心的发现,尽管其结构与GNE-0723相似。GNE-5729(),一种基于吡啶并嘧啶酮的NMDAR PAM,被鉴定出具有改善的药代动力学特征以及对AMPA受体更高的选择性。我们还纳入了X射线结构分析和建模,以提出关于活性和选择性差异的假说。